Given the COVID-19 pandemic, there has been a temporary suspension of study activities, therefore the study has not yet been initiated.

Nausea and vomiting is a common and distressing presenting complaint in Canadian emergency departments. Commonly used nausea medications have proven to be effective in certain patient populations, for example cancer patients. However, not one has been proven to be more effective that the other in the emergency department setting. In addition, many are associated with significant side effects and have the potential to interact with a patient's home medications. This limits their use in the emergency department until the patient is seen and assessed by their treating physician.

Many studies have shown that nasal inhalation of alcohol swabs is an effective therapy in relieving nausea and vomiting in post-operative patients after surgeries. The goal of this study will be to determine the effectiveness of alcohol swabs in the emergency department setting in relieving nausea and vomiting.

BACKGROUND INFORMATION:

Emerging evidence exists supporting the use of nasally inhaled isopropyl alcohol swabs as anti-emetic therapy. Multiple studies report isopropyl alcohol inhalation as an effective treatment for post-operative nausea and vomiting, with no reported adverse events. This relatively inexpensive substance is widely available in most health care settings in the form of swabs used in the routine course of delivering care as an antiseptic skin cleanser. Two previous studies in the United States have evaluated the use of inhaled isopropyl alcohol swabs in alleviating nausea and vomiting in the emergency department setting. One study in 2016 study by Beadle et. al. demonstrated superior nausea relief using inhaled isopropyl alcohol swabs compared to an inhaled placebo, while a 2018 study by April et. al. demonstrated superior nausea relief with isopropyl alcohol swabs compared with inhaled placebo and oral ondansetron.

The 2016 study by Beadle et. al. has several important limitations. This was a single center military hospital study, which only measured nausea scores 10 minutes after isopropyl alcohol swab inhalation, and lacked other important outcomes such as the number of vomiting episodes, use of rescue anti-emetics, ED length of stay and admission rates. The 2018 study by April et. al. also has limitations. Mainly, alcohol swabs were used as often as required by participants, and the dosing frequency of inhalations was not measured. They also excluded patients who had a peripheral intravenous catheter inserted on arrival, which could suggest that patients with more severe symptoms of nausea and vomiting requiring intravenous anti-emetics were excluded.

STUDY RATIONALE:

The investigator's goal is to add to the current body of evidence on the use of isopropyl alcohol in alleviating nausea and vomiting in the emergency department, particularly by determining which dosing frequency of isopropyl alcohol inhalation yields the most effective nausea relief by randomizing patients to different inhalation frequencies. This may help to guide future triage protocols enabling isopropyl alcohol inhalation before provider evaluation to improve treatment of nausea and patient satisfaction. In the current state of emergency department overcrowding, the ability to adequately control a patient's symptoms at triage may help decrease a patient's length of stay, as well as the number of patients requiring beds. In addition, from a cost-savings perspective, alcohol swabs are a relatively inexpensive therapy as compared to many commonly administered anti-emetics.

OBJECTIVES:

The objective of this study is to determine the efficacy of nasally inhaled isopropyl alcohol in alleviating nausea and/or vomiting in patients presenting to the emergency department with a chief complaint of nausea and/or vomiting. Specifically, this study will determine:

1. Nausea relief: mean reduction in nausea scores using a self-reported nausea scale comparing the pre-intervention nausea score to the final nausea score at the study endpoint.
2. Participant satisfaction: self-reported satisfaction scale measured at the study endpoint.
3. Optimal dosing frequency: compare the reduction in nausea scores among participants inhaling isopropyl alcohol swabs every 10 minutes, every 20 minutes, and to participants receiving no intervention.
4. Emergency department management: receipt of rescue anti-emetic medications and other medications (ie. analgesics, intravenous fluids).
5. Participant disposition: emergency department length of stay and admission to hospital.

OUTCOMES:

The primary outcome reflecting the efficacy of treatment is the mean nausea score reduction, using a self-reported nausea score comparing the subject's pre-intervention score to the final nausea score at the study endpoint. Nausea scores will be measured using a self-reported 10-point verbal numeric scale ranging from 1-10, labeled "no nausea" at the left end (1) and "worse nausea imaginable" at right end (10). Nausea scores will be measured at baseline before intervention, 10 minutes post-intervention, 20 minutes post-intervention, 30 minutes post-intervention, and then every 30 minutes for a total of two hours throughout the subject's emergency department visit.

The secondary outcomes reflecting the efficacy of the study intervention are participant satisfaction scores, the receipt of any rescue anti-emetic medications, emergency department length of stay, and participant disposition. Satisfaction scores will be measured using a self-reported 5-point verbal numeric scale ranging from 1-5, labeled "very unsatisfied" at the left end (1) and "very satisfied" at the right end (5).

STUDY DESIGN:

This study will be a randomized controlled trial of eligible patients presenting to the emergency department with a chief complaint of nausea and/or vomiting. Study subjects will be randomized to one of three subject arms: 1) Nasally inhaled isopropyl alcohol swabs every 10 minutes for a total of one hour; 2) Nasally inhaled isopropyl alcohol swabs every 20 minutes for a total of one hour; and 3) No intervention arm.

A convenience sample of potential study subjects will be identified by the research team during periods when available to enroll subjects. Patients will be approached while in the waiting room or shortly after arrival to their assigned emergency department room, before arrival of their treating physician and before any treatment is provided.

The allocation sequence will be generated using computer-generated random numbers using blocks of 6. Concealment will be performed using sealed, opaque envelopes.

STUDY DURATION:

Subject participation will be expected to end at the study endpoint, either after two hours of collection of nausea scores from the start of treatment or until there is administration of anti-emetics from the treating physician before the two hours is complete. There will be no further follow-up. Active study duration will be two hours for each study participant.

SAMPLE SIZE:

The minimally clinically significant difference is assumed to be 3 points on a self-reported 10-point verbal numeric scale ranging from 1-10. For α=0.25 and β=.80 using a t-test, the sample size required is 45 per participant arm (135 participants total). Imputation will be used to replace any missing data.

STATISTICAL METHODS:

All analysis will be done by the trial biostatistician. Participant baseline characteristics will be summarized with descriptive statistics with 95% confidence intervals. The primary outcome, i.e., mean reduction in nausea scores, will be analyzed using repeated measures linear regression analysis. Study arm, time and study arm by time will be included as fixed covariates and the correlation in repeated measures on the same subject over time will be modeled using a suitable covariance structure. Least square mean differences, together with 95% Confidence Intervals, will be used to express the treatment effect, comparing each of the intervention arms to the control arm. Statistical significance of each pairwise comparison will be judged at the 2.5% level to maintain the overall level at 5%. A similar approach will be used for ED lengths of stay (with transformation to improve normality if necessary). Number of vomiting episodes and receipt of antiemetic drugs will be analyzed using Poisson or logistic regression as appropriate. All analyses will be intention to treat. There will be no interim analysis completed. Imputation will be used to replace any missing data.

QUALITY CONTROL:

The study will have a quality control monitoring process and study monitor plan in place to verify that all data are accurate and complete. An internal DSMB, free of competing interests, will monitor the study and will generate a site monitoring report to detail significant findings, deviations, deficiencies, plausibility, record completeness and any corrective actions to be taken. The investigator will permit trial-related monitoring, audits, REB review, and regulatory inspection(s) by providing direct access to source data/documents.

Inclusion Criteria:

• Adult patients (age ≥18 years) presenting to the emergency department with a chief complaint of nausea and/or vomiting with a level of 3 or greater on a verbal numeric response scale (1-10).

Exclusion Criteria:

• Not able to breathe through nares (ie. rhinitis)
• Known pregnancy
• Have already received an anti-emetic within the past 24 hours (including while in emergency department triage)
• Chronic nausea (> 1 month)
• Known allergy to isopropyl alcohol
• Nasally sensitive to inhaled chemical products
• Altered mental status or underlying cognitive impairment

The trial design is open label, given that blinding the scent of alcohol swabs is difficult. As such, no blinding of the study participants nor the research team to interventions will occur, as there will be no placebo intervention given.